I think it's important to have realistic expectations, although obviously we can all dream! I'm looking for 15-20 cents in the next 6 months on full clinical data and further disclosure regarding Onyx combination trial, as I view a market cap of $100-150m as undemanding given what PAB has achieved to date. Looking at the performance of coys like AHZ, ADO and PSY and the renewed institutional interest in the biotech sector I believe that PAB is due for a re-rate, particularly once the RI shortfall is either placed or reaches its expiry after 3 months.
In the event of a licensing agreement for SM6 then yes the sky's the limit, the Bell Potter report had a $ value range of $100-200m from memory for SM6. If such a deal occurs, then think about the number of trials that can be funded as a result, SM6 is the tip of the iceberg! To me, that is the holy grail.
GLTA
- Forums
- ASX - By Stock
- 2014.... your thoughts and predictions
I think it's important to have realistic expectations, although...
-
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.6¢ | 0.7¢ | 0.6¢ | $589 | 91.50K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 4759154 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1636778 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 4759154 | 0.006 |
13 | 6829276 | 0.005 |
7 | 4425000 | 0.004 |
4 | 2729016 | 0.003 |
2 | 4520000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1636778 | 2 |
0.008 | 4991280 | 4 |
0.010 | 1592000 | 4 |
0.011 | 1080000 | 2 |
0.012 | 552407 | 4 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |